Harry Quon, MD, Gregory S. Weinstein, MD, and Bert W. O'Malley, Jr., MD, contributed equally to this work as first authors.
Head and Neck
Transoral robotic surgery and adjuvant therapy for oropharyngeal carcinomas and the influence of p16INK4a on treatment outcomes†
Article first published online: 1 FEB 2013
Copyright © 2013 The American Laryngological, Rhinological, and Otological Society, Inc.
Volume 123, Issue 3, pages 635–640, March 2013
How to Cite
Quon, H., Cohen, M. A., Montone, K. T., Ziober, A. F., Wang, L. P., Weinstein, G. S. and O'Malley, B. W. (2013), Transoral robotic surgery and adjuvant therapy for oropharyngeal carcinomas and the influence of p16INK4a on treatment outcomes. The Laryngoscope, 123: 635–640. doi: 10.1002/lary.22172
The authors have no funding, financial relationships, or conflicts of interest to disclose.
- Issue published online: 26 FEB 2013
- Article first published online: 1 FEB 2013
- Accepted manuscript online: 20 JUL 2011 11:11AM EST
- Manuscript Accepted: 18 APR 2011
- Manuscript Revised: 13 APR 2011
- Manuscript Received: 17 JAN 2011
- oropharyngeal carcinoma;
- human papilloma virus;
- transoral robotic surgery;
- Level of Evidence: 2b.
To determine the prognostic influence of p16INK4a immunohistochemistry on the survival of resectable oropharyngeal carcinomas (OPSCC).
Retrospective pathologic evaluation of a prospective single-arm cohort study at a tertiary referral center.
There were 48 patients with resectable OPSCC who consented for transoral robotic surgery (TORS) and banked tissue specimen for assessment. TORS was with or without adjuvant radiation or chemoradiation. Main outcome measures were p16INK4a status, human papillomavirus status, local-regional disease control, and overall, disease-specific, and disease-free survival.
p16INK4a and HPV positivity were identified in 73% and 74% of patients respectively. With a median follow-up of 38.8 months (2.5–63.3 months), only one local-regional relapse has occurred in both the p16INK4a-positive and p16INK4a-negative cohorts. No disease-specific, disease-free, and overall survival differences were observed between p16INK4a-positive and p16INK4a-negative patients (P = .446, P = .277, P = .643, respectively).
p16INK4a was not prognostic in resectable OPSCC when treated with an initial TORS approach. Laryngoscope, 2013